Journal Article

DKFZ-2026-01672

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

Fanti, S. ; Turco, F. ; Tombal, B. ; Walz, J. ; Hofman, M. S. ; Hadaschik, B.DKFZ* ; Emmett, L. ; Tilki, D. ; Pecoraro, G. ; Salfi, G. ; Attard, G. ; Beltran, H. ; Bjartell, A. ; Briganti, A. ; Burger, I. A. ; Castro, E. ; Cerci, J. J. ; Chiti, A. ; Cooperberg, M. ; Fizazi, K. ; Fossati, N. ; Gafita, A. ; Gallina, A. ; Goffin, K. ; Horvath, L. G. ; Hugosson, J. ; Iagaru, A. ; James, N. D. ; Kasivisvanathan, V. ; Koh, D.-M. ; Kristiansen, G. ; Kumar, R. ; Lecouvet, F. ; Loeb, S. ; McKay, R. R. ; Morris, M. J. ; Murphy, D. G. ; Murthy, V. ; Naoun, N. ; Oprea-Lager, D. E. ; Ost, P. ; O'Sullivan, J. ; Padhani, A. R. ; Palapattu, G. ; Paone, G. ; Petralia, G. ; Roobol, M. J. ; Sartor, O. A. ; Sathekge, M. ; Schuster, D. M. ; Seibert, T. M. ; Spratt, D. E. ; Tempany, C. ; Tunariu, N. ; Vargas, H. A. ; Vogl, U. M. ; Wyatt, A. W. ; Zilli, T. ; Lin, H.-M. ; Omlin, A. ; Gillessen, S. ; Herrmann, K.DKFZ*

2026
Elsevier Science Amsterdam [u.a.]

Abstract: For over a decade the Advanced Prostate Cancer Consensus Conference (APCCC) covers a variety of topics that greatly impact daily practice. In 2025, a dedicated event was organised to discuss key questions in clinical management of patients with prostate cancer (PC) related to diagnostic tools (APCCC Diagnostics). Here we present the voting results of the APCCC Diagnostics questions. OBJECTIVE; DESIGN, SETTING, AND PARTECIPANTS: APCCC Diagnostics 2025 is a pilot project. The scientific committee for APCCC Diagnostics 2025 developed 88 multiple-choice consensus questions on six different topics. Prior to the conference, the panel members (''panellists'') voted on these questions via a web-based survey. Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement.Consensus was only reached on 17 of 88 questions (19%), of which six (7%) received a strong consensus. Specifically, consensus was reached for two of 17 questions (14%) in 'how to diagnose PC'; seven of 16 (44%) in 'how to stage PC'; three of 14 (21%) in 'Biochemical Recurrence Scenario'; two of 11 (18%) in 'metastatic disease: what to do?'; zero of 18 (0%) in 'monitoring metastatic PC'; and three of 12 (25%) in 'radioligand therapy and imaging.'The voting results and their discussion may assist physicians in navigating controversial areas of clinical management related to diagnosis, staging, and restaging in the different clinical settings for PC, particularly where high-level evidence is scarce or conflicting. The findings can also help funders and policymakers in prioritising areas for future research.

Keyword(s): biochemical recurrence ; metastatic prostate cancer ; prostate cancer ; radioligand therapy

Note: #DKTKZFB9# / epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 20 ; JCR ; National-Konsortium ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---